SlideServe
Télécharger Obtenir Pro
Menu
Accueil Pro
Préférences
ApparenceLight Aide et commentaires
© SlideServe · v2026

Recent HCV treatment developments: In pursuit of perfectovir

acton avatar
acton
29 diapositives · 620 Views · Oct 09, 2014

Recent HCV treatment developments: In pursuit of perfectovir. Professor Greg Dore Kirby Institute, UNSW Australia; & St Vincent’s Hospital, Sydney. HCV treatment strategies: Australia. PEG-IFN + RBV. PEG-IFN + RBV + DAA. Treatment complexity. IFN-free DAA combination. 2011.

#recent hcv treatment developments: in pursuit of perfectovir #recent hcv treatment developments: in pursuit of perfectovir ppt #powerpoint #presentation
Recent HCV treatment developments: In pursuit of perfectovir - slide 1
01 / 29Recent HCV treatment developments: In pursuit of perfectovir
1 / 17

Télécharger la présentation

Recent HCV treatment developments: In pursuit of perfectovir
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation

  1. Recent HCV treatment developments:In pursuit of perfectovir Professor Greg Dore Kirby Institute, UNSW Australia; & St Vincent’s Hospital, Sydney

  2. HCV treatment strategies: Australia PEG-IFN + RBV PEG-IFN + RBV + DAA Treatment complexity IFN-free DAA combination 2011 2012 2013 2014 2015 2016 Dore GJ. MJA 2012 (revised)

  3. HCV treatment strategies: United States PEG-IFN + RBV PEG-IFN + RBV + DAA Treatment complexity IFN-free DAA combination 2011 2012 2013 2014 2015 2016 Dore GJ. MJA 2012 (revised)

  4. HCV life cycle Liang TJ & Ghany MG. NEJM 2013;368:1907-1917

  5. HCV therapeutic development X X ? Welsch & Zeuzum. Gastroenterology 2012;142:1351-1355

  6. Key recent HCV therapeutic development findings: • Sofosbuvir (nucleotide analogue) and Simeprevir (protease inhibitor) licensure for GT1 has revealed the future = IFN-free dual DAA short duration therapy (12 weeks) • Several highly curative GT1 IFN-free DAA regimens will be available • HCV GT3 therapeutic solution less advanced, but pangenotypic regimens likely • HIV does not impair response to IFN-free DAA therapy • HCV resistance will not be a major clinical issue • Ultimately limited individualisation required

  7. HCV therapeutic development Key attributes of perfectovir • Extremely high efficacy (>95%) • Minimal toxicity • Once daily dosing • Pangenotypic • Short duration (4-6 weeks)

  8. HCV therapeutic development Key attributes of perfectovir • Extremely high efficacy (>95%) • Minimal toxicity • Once daily dosing • Pangenotypic • Short duration (4-6 weeks)

  9. NEUTRINO: PEG-IFN/RBV/Sofosbuvir • Genotype 1 (+4/5/6) treatment naïve, 12 weeks SVR12 % Lawitz E et al. NEJM 2013;368:1878-1887

  10. Abbvie: ABT-450/r/Ombitasvir/Dasabuvir • Genotype 1, treatment naïve and experienced SVR12 % Sapphire-I & II Pearl-IV & Turquoise-II Pearl-II & III Zeuzem S, et al. NEJM 2014;370:1604-1614; Poordad F, et al. NEJM 2014; Feld JJ, et al. NEJM 2014

  11. Gilead: Sofosbuvir/Ledipasvir • Genotype 1, treatment naive and experienced SVR 12 % ION-1 (16% cirrhosis) ION-2 (20% cirrhosis) ION-3 Afdhal N, et al. NEJM 2014;370:1483-1493; Afdhal N, et al. NEJM 2014; Kowdley KV, et al. NEJM 2014

  12. COSMOS: Sofosbuvir/Simeprevir • Genotype 1, treatment naive and experienced, 12 weeks SVR 12 % Jacobson I, et al. AASLD 2013

  13. Sofosbuvir/Ribavirin vs PEG-IFN/RBV • Genotype 2, treatment naive, 12 weeks vs 24 weeks SVR 12 % Lawitz E et al. NEJM 2013;368:1878-1887

  14. Sofosbuvir/Ribavirin • Genotype 3, treatment naïve and experienced, 24 weeks SVR 12 % Zeuzem S et al, AASLD 2013

  15. HCV therapeutic development Key attributes of perfectovir • Extremely high efficacy (>95%) • Minimal toxicity • Once daily dosing • Pangenotypic • Short duration (4-6 weeks)

  16. HCV prevalence and genotype distribution Hajarizadeh B, Grebely J, Dore GJ. Nat Rev GastroenterolHepatol 2013

  17. Sofosbuvir/GS-5816 • Treatment naïve, F0-3, 12 weeks SVR12 % Everson GT, et al. ILC2014

  18. HCV therapeutic development Key attributes of perfectovir • Extremely high efficacy (>95%) • Minimal toxicity • Once daily dosing • Pangenotypic • Short duration (4-6 weeks)

  19. Sofosbuvir/Ledipasvir • Genotype 1, treatment naïve, F0-2 SVR 12 % Lawitz E et al, AASLD 2013; Gane E et al, AASLD 2013

  20. Sofosbuvir/Ledipasvir • Genotype 1, treatment naïve, F0-2 SVR 12 % Lawitz E et al, AASLD 2013; Gane E et al, AASLD 2013

  21. Sofosbuvir/Ledipasvir • Genotype 1, treatment naïve, F0-2 SVR 12 % Lawitz E et al, AASLD 2013; Gane E et al, AASLD 2013

  22. Sofosbuvir/Ledipasvir/3rdDAA • Genotype 1, treatment naïve, F0-3 SVR 12 % Kohli A et al, AASLD 2013

  23. Sofosbuvir/Ledipasvir/3rdDAA • Genotype 1, treatment naïve, F0-3 SVR12 % Kohli A et al, AASLD 2013

  24. HCV regimen approval timelines: Australia

  25. HCV regimen approval timelines: Australia PEG + RBV + TPV/BCP PEG + RBV 2014 2015 2016 2017 2018 2019 2020

  26. HCV regimen approval timelines: Australia TGA PBAC IFN-free: Sofosbuvir + Ribavirin (G2/3) TGA PBAC PEG + RBV + Sofosbuvir / Simeprevir (G1) PEG + RBV + TPV/BCP PEG + RBV 2014 2015 2016 2017 2018 2019 2020

  27. HCV regimen approval timelines: Australia TGA PBAC IFN-free: Sofosbuvir + Ledipasvir(G1) TGA PBAC IFN-free: ABT450/r + Ombitasvir + Dasabuvir +/- Ribavirin (G1) TGA PBAC IFN-free: Sofosbuvir + Ribavirin (G2/3) TGA PBAC PEG + RBV + Sofosbuvir / Simeprevir (G1) PEG + RBV + TPV/BCP PEG + RBV 2014 2015 2016 2017 2018 2019 2020

  28. HCV regimen approval timelines: Australia TGA PBAC IFN-free: Sofosbuvir + GS-5816 (GT1-6) TGA PBAC IFN-free: Sofosbuvir + Ledipasvir(G1) TGA PBAC IFN-free: ABT450/r + Ombitasvir + Dasabuvir +/- Ribavirin (G1) TGA PBAC IFN-free: Sofosbuvir + Ribavirin (G2/3) TGA PBAC PEG + RBV + Sofosbuvir / Simeprevir (G1) PEG + RBV + TPV/BCP PEG + RBV 2014 2015 2016 2017 2018 2019 2020

  29. HCV therapeutic development A few caveats • High drug pricing • Probable disease stage restriction for IFN-free DAA therapy • Potential treatment caps But • Several pharma companies should ensure competitive pricing • Ability to cure close to 100% should empower the sector